ID   MK12_HUMAN              Reviewed;         367 AA.
AC   P53778; Q14260; Q99588; Q99672;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   15-JUL-1998, sequence version 3.
DT   05-OCT-2010, entry version 125.
DE   RecName: Full=Mitogen-activated protein kinase 12;
DE            Short=MAP kinase 12;
DE            Short=MAPK 12;
DE            EC=2.7.11.24;
DE   AltName: Full=Extracellular signal-regulated kinase 6;
DE            Short=ERK-6;
DE   AltName: Full=Mitogen-activated protein kinase p38 gamma;
DE            Short=MAP kinase p38 gamma;
DE   AltName: Full=Stress-activated protein kinase 3;
GN   Name=MAPK12; Synonyms=ERK6, SAPK3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, TISSUE SPECIFICITY, AND
RP   MUTAGENESIS OF TYR-185.
RC   TISSUE=Skeletal muscle;
RX   MEDLINE=96210647; PubMed=8633070; DOI=10.1073/pnas.93.9.4355;
RA   Lechner C., Zahalka M.A., Giot J.-F., Moeller N.P.H., Ullrich A.;
RT   "ERK6, a mitogen-activated protein kinase involved in C2C12 myoblast
RT   differentiation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 93:4355-4359(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Skeletal muscle;
RX   MEDLINE=97312715; PubMed=9169156; DOI=10.1006/geno.1997.4633;
RA   Goedert M., Hasegawa J., Craxton M., Leversha M.A., Clegg S.;
RT   "Assignment of the human stress-activated protein kinase-3 gene
RT   (SAPK3) to chromosome 22q13.3 by fluorescence in situ hybridization.";
RL   Genomics 41:501-502(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   MEDLINE=97079183; PubMed=8920915; DOI=10.1006/bbrc.1996.1662;
RA   Li Z., Jiang Y., Ulevitch R.J., Han J.;
RT   "The primary structure of p38 gamma: a new member of p38 group of MAP
RT   kinases.";
RL   Biochem. Biophys. Res. Commun. 228:334-340(1996).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   MEDLINE=20057165; PubMed=10591208; DOI=10.1038/990031;
RA   Dunham I., Hunt A.R., Collins J.E., Bruskiewich R., Beare D.M.,
RA   Clamp M., Smink L.J., Ainscough R., Almeida J.P., Babbage A.K.,
RA   Bagguley C., Bailey J., Barlow K.F., Bates K.N., Beasley O.P.,
RA   Bird C.P., Blakey S.E., Bridgeman A.M., Buck D., Burgess J.,
RA   Burrill W.D., Burton J., Carder C., Carter N.P., Chen Y., Clark G.,
RA   Clegg S.M., Cobley V.E., Cole C.G., Collier R.E., Connor R.,
RA   Conroy D., Corby N.R., Coville G.J., Cox A.V., Davis J., Dawson E.,
RA   Dhami P.D., Dockree C., Dodsworth S.J., Durbin R.M., Ellington A.G.,
RA   Evans K.L., Fey J.M., Fleming K., French L., Garner A.A.,
RA   Gilbert J.G.R., Goward M.E., Grafham D.V., Griffiths M.N.D., Hall C.,
RA   Hall R.E., Hall-Tamlyn G., Heathcott R.W., Ho S., Holmes S.,
RA   Hunt S.E., Jones M.C., Kershaw J., Kimberley A.M., King A.,
RA   Laird G.K., Langford C.F., Leversha M.A., Lloyd C., Lloyd D.M.,
RA   Martyn I.D., Mashreghi-Mohammadi M., Matthews L.H., Mccann O.T.,
RA   Mcclay J., Mclaren S., McMurray A.A., Milne S.A., Mortimore B.J.,
RA   Odell C.N., Pavitt R., Pearce A.V., Pearson D., Phillimore B.J.C.T.,
RA   Phillips S.H., Plumb R.W., Ramsay H., Ramsey Y., Rogers L., Ross M.T.,
RA   Scott C.E., Sehra H.K., Skuce C.D., Smalley S., Smith M.L.,
RA   Soderlund C., Spragon L., Steward C.A., Sulston J.E., Swann R.M.,
RA   Vaudin M., Wall M., Wallis J.M., Whiteley M.N., Willey D.L.,
RA   Williams L., Williams S.A., Williamson H., Wilmer T.E., Wilming L.,
RA   Wright C.L., Hubbard T., Bentley D.R., Beck S., Rogers J., Shimizu N.,
RA   Minoshima S., Kawasaki K., Sasaki T., Asakawa S., Kudoh J.,
RA   Shintani A., Shibuya K., Yoshizaki Y., Aoki N., Mitsuyama S.,
RA   Roe B.A., Chen F., Chu L., Crabtree J., Deschamps S., Do A., Do T.,
RA   Dorman A., Fang F., Fu Y., Hu P., Hua A., Kenton S., Lai H., Lao H.I.,
RA   Lewis J., Lewis S., Lin S.-P., Loh P., Malaj E., Nguyen T., Pan H.,
RA   Phan S., Qi S., Qian Y., Ray L., Ren Q., Shaull S., Sloan D., Song L.,
RA   Wang Q., Wang Y., Wang Z., White J., Willingham D., Wu H., Yao Z.,
RA   Zhan M., Zhang G., Chissoe S., Murray J., Miller N., Minx P.,
RA   Fulton R., Johnson D., Bemis G., Bentley D., Bradshaw H., Bourne S.,
RA   Cordes M., Du Z., Fulton L., Goela D., Graves T., Hawkins J.,
RA   Hinds K., Kemp K., Latreille P., Layman D., Ozersky P., Rohlfing T.,
RA   Scheet P., Walker C., Wamsley A., Wohldmann P., Pepin K., Nelson J.,
RA   Korf I., Bedell J.A., Hillier L.W., Mardis E., Waterston R.,
RA   Wilson R., Emanuel B.S., Shaikh T., Kurahashi H., Saitta S.,
RA   Budarf M.L., McDermid H.E., Johnson A., Wong A.C.C., Morrow B.E.,
RA   Edelmann L., Kim U.J., Shizuya H., Simon M.I., Dumanski J.P.,
RA   Peyrard M., Kedra D., Seroussi E., Fransson I., Tapia I., Bruder C.E.,
RA   O'Brien K.P., Wilkinson P., Bodenteich A., Hartman K., Hu X.,
RA   Khan A.S., Lane L., Tilahun Y., Wright H.;
RT   "The DNA sequence of human chromosome 22.";
RL   Nature 402:489-495(1999).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Pancreas;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   INTERACTION WITH SNTA1.
RX   MEDLINE=99230285; PubMed=10212242; DOI=10.1074/jbc.274.18.12626;
RA   Hasegawa M., Cuenda A., Spillantini M.G., Thomas G.M.,
RA   Buee-Scherrer V., Cohen P., Goedert M.;
RT   "Stress-activated protein kinase-3 interacts with the PDZ domain of
RT   alpha1-syntrophin. A mechanism for specific substrate recognition.";
RL   J. Biol. Chem. 274:12626-12631(1999).
RN   [7]
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RC   TISSUE=Heart;
RX   MEDLINE=21988345; PubMed=11991731; DOI=10.1006/jmcc.2001.1523;
RA   Court N.W., dos Remedios C.G., Cordell J., Bogoyevitch M.A.;
RT   "Cardiac expression and subcellular localization of the p38 mitogen-
RT   activated protein kinase member, stress-activated protein kinase-3
RT   (SAPK3).";
RL   J. Mol. Cell. Cardiol. 34:413-426(2002).
RN   [8]
RP   MUTAGENESIS, SUBCELLULAR LOCATION, AND INTERACTION WITH SH3BP5.
RX   MEDLINE=22280328; PubMed=12167088; DOI=10.1042/BJ20020553;
RA   Wiltshire C., Matsushita M., Tsukada S., Gillespie D.A., May G.H.;
RT   "A new c-Jun N-terminal kinase (JNK)-interacting protein, Sab
RT   (SH3BP5), associates with mitochondria.";
RL   Biochem. J. 367:577-585(2002).
RN   [9]
RP   MUTAGENESIS OF ASP-179 AND PHE-330.
RX   PubMed=15284239; DOI=10.1074/jbc.M404595200;
RA   Diskin R., Askari N., Capone R., Engelberg D., Livnah O.;
RT   "Active mutants of the human p38alpha mitogen-activated protein
RT   kinase.";
RL   J. Biol. Chem. 279:47040-47049(2004).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-27, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-185, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Lung carcinoma;
RX   PubMed=18083107; DOI=10.1016/j.cell.2007.11.025;
RA   Rikova K., Guo A., Zeng Q., Possemato A., Yu J., Haack H., Nardone J.,
RA   Lee K., Reeves C., Li Y., Hu Y., Tan Z., Stokes M., Sullivan L.,
RA   Mitchell J., Wetzel R., Macneill J., Ren J.M., Yuan J.,
RA   Bakalarski C.E., Villen J., Kornhauser J.M., Smith B., Li D., Zhou X.,
RA   Gygi S.P., Gu T.-L., Polakiewicz R.D., Rush J., Comb M.J.;
RT   "Global survey of phosphotyrosine signaling identifies oncogenic
RT   kinases in lung cancer.";
RL   Cell 131:1190-1203(2007).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RA   Colinge J., Superti-Furga G., Bennett K.L.;
RL   Submitted (OCT-2008) to UniProtKB.
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-3 AND TYR-185, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Embryonic kidney;
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS), COFACTOR, AND SUBUNIT.
RX   PubMed=10508788; DOI=10.1016/S0969-2126(99)80173-7;
RA   Bellon S., Fitzgibbon M.J., Fox T., Hsiao H.M., Wilson K.P.;
RT   "The structure of phosphorylated p38gamma is monomeric and reveals a
RT   conserved activation-loop conformation.";
RL   Structure 7:1057-1065(1999).
RN   [15]
RP   VARIANTS [LARGE SCALE ANALYSIS] MET-103 AND ASN-230.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Responds to activation by environmental stress and pro-
CC       inflammatory cytokines by phosphorylating downstream targets.
CC       Plays a role in myoblast differentiation and also in the down-
CC       regulation of cyclin D1 in response to hypoxia in adrenal cells
CC       suggesting MAPK12 may inhibit cell proliferation while promoting
CC       differentiation.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- COFACTOR: Binds 2 magnesium ions.
CC   -!- ENZYME REGULATION: Activated by phosphorylation on threonine and
CC       tyrosine (By similarity).
CC   -!- SUBUNIT: Monomer. Interacts with the PDZ domain of the syntrophin
CC       SNTA1. Interacts with SH3BP5.
CC   -!- INTERACTION:
CC       Q16512:PKN1; NbExp=1; IntAct=EBI-602406, EBI-602382;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Mitochondrion. Note=Mitochondrial
CC       when associated with SH3BP5.
CC   -!- TISSUE SPECIFICITY: Highly expressed in skeletal muscle and heart.
CC   -!- DOMAIN: The TXY motif contains the threonine and tyrosine residues
CC       whose phosphorylation activates the MAP kinases.
CC   -!- PTM: Dually phosphorylated on Thr-183 and Tyr-185, which activates
CC       the enzyme (By similarity).
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CMGC
CC       Ser/Thr protein kinase family. MAP kinase subfamily.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X79483; CAA55984.1; -; mRNA.
DR   EMBL; Y10487; CAA71511.1; -; mRNA.
DR   EMBL; U66243; AAB40118.1; -; mRNA.
DR   EMBL; AL022328; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC015741; AAH15741.1; -; mRNA.
DR   IPI; IPI00296283; -.
DR   PIR; JC5252; JC5252.
DR   PIR; JC6138; JC6138.
DR   RefSeq; NP_002960.2; -.
DR   UniGene; Hs.432642; -.
DR   PDB; 1CM8; X-ray; 2.40 A; A/B=1-367.
DR   PDBsum; 1CM8; -.
DR   ProteinModelPortal; P53778; -.
DR   IntAct; P53778; 2.
DR   MINT; MINT-90266; -.
DR   STRING; P53778; -.
DR   PhosphoSite; P53778; -.
DR   PRIDE; P53778; -.
DR   Ensembl; ENST00000215659; ENSP00000215659; ENSG00000188130.
DR   GeneID; 6300; -.
DR   KEGG; hsa:6300; -.
DR   NMPDR; fig|9606.3.peg.21965; -.
DR   UCSC; uc003bkm.1; human.
DR   CTD; 6300; -.
DR   GeneCards; GC22M050684; -.
DR   H-InvDB; HIX0016608; -.
DR   HGNC; HGNC:6874; MAPK12.
DR   HPA; CAB025483; -.
DR   MIM; 602399; gene.
DR   PharmGKB; PA30619; -.
DR   eggNOG; prNOG04474; -.
DR   HOGENOM; HBG755340; -.
DR   HOVERGEN; HBG014652; -.
DR   InParanoid; P53778; -.
DR   OMA; MGTDLSK; -.
DR   OrthoDB; EOG94F8VP; -.
DR   PhylomeDB; P53778; -.
DR   BRENDA; 2.7.11.24; 247.
DR   Pathway_Interaction_DB; p38gammadeltapathway; Signaling mediated by p38-gamma and p38-delta.
DR   Reactome; REACT_11061; Signalling by NGF.
DR   Reactome; REACT_21303; Myogenesis.
DR   NextBio; 24459; -.
DR   ArrayExpress; P53778; -.
DR   Bgee; P53778; -.
DR   CleanEx; HS_MAPK12; -.
DR   Genevestigator; P53778; -.
DR   GermOnline; ENSG00000188130; Homo sapiens.
DR   GO; GO:0005739; C:mitochondrion; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0000287; F:magnesium ion binding; IDA:UniProtKB.
DR   GO; GO:0004707; F:MAP kinase activity; TAS:ProtInc.
DR   GO; GO:0005515; F:protein binding; IPI:UniProtKB.
DR   GO; GO:0007050; P:cell cycle arrest; TAS:ProtInc.
DR   GO; GO:0006975; P:DNA damage induced protein phosphorylation; TAS:ProtInc.
DR   GO; GO:0007517; P:muscle organ development; TAS:ProtInc.
DR   GO; GO:0045445; P:myoblast differentiation; IDA:UniProtKB.
DR   GO; GO:0007265; P:Ras protein signal transduction; EXP:Reactome.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR003527; MAP_kinase_CS.
DR   InterPro; IPR008352; MAPK_p38.
DR   InterPro; IPR000719; Prot_kinase_cat_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR017442; Se/Thr_prot_kinase-like_dom.
DR   InterPro; IPR002290; Ser/Thr_prot_kinase_dom.
DR   Pfam; PF00069; Pkinase; 1.
DR   PRINTS; PR01773; P38MAPKINASE.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; Kinase_like; 1.
DR   PROSITE; PS01351; MAPK; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; FALSE_NEG.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Cell cycle; Complete proteome; Cytoplasm;
KW   Kinase; Magnesium; Metal-binding; Mitochondrion; Nucleotide-binding;
KW   Phosphoprotein; Polymorphism; Serine/threonine-protein kinase;
KW   Transferase.
FT   CHAIN         1    367       Mitogen-activated protein kinase 12.
FT                                /FTId=PRO_0000186282.
FT   DOMAIN       27    311       Protein kinase.
FT   NP_BIND      33     41       ATP (By similarity).
FT   MOTIF       183    185       TXY.
FT   ACT_SITE    153    153       Proton acceptor (By similarity).
FT   BINDING      56     56       ATP (By similarity).
FT   MOD_RES       3      3       Phosphoserine.
FT   MOD_RES      27     27       Phosphotyrosine.
FT   MOD_RES     183    183       Phosphothreonine (By similarity).
FT   MOD_RES     185    185       Phosphotyrosine.
FT   VARIANT     103    103       T -> M (in dbSNP:rs34422484).
FT                                /FTId=VAR_042265.
FT   VARIANT     230    230       D -> N (in dbSNP:rs35396905).
FT                                /FTId=VAR_042266.
FT   VARIANT     244    244       T -> M (in dbSNP:rs2066776).
FT                                /FTId=VAR_012002.
FT   MUTAGEN     179    179       D->A: Emulation of the active state.
FT   MUTAGEN     185    185       Y->F: Loss of activity.
FT   MUTAGEN     330    330       F->S: No effect.
FT   CONFLICT      7      7       A -> T (in Ref. 1; CAA55984).
FT   CONFLICT     70     70       R -> L (in Ref. 1; CAA55984).
FT   CONFLICT    138    138       L -> M (in Ref. 1; CAA55984).
FT   CONFLICT    201    202       MR -> IA (in Ref. 1; CAA55984).
FT   CONFLICT    261    261       Y -> N (in Ref. 3; AAB40118).
FT   CONFLICT    297    298       EQ -> DI (in Ref. 1; CAA55984).
FT   CONFLICT    300    300       V -> L (in Ref. 1; CAA55984).
FT   CONFLICT    305    305       A -> F (in Ref. 1; CAA55984).
FT   CONFLICT    307    307       A -> S (in Ref. 1; CAA55984).
FT   CONFLICT    332    333       DV -> YF (in Ref. 1; CAA55984).
FT   STRAND       17     21
FT   STRAND       24     32
FT   STRAND       41     46
FT   TURN         47     49
FT   STRAND       52     57
FT   HELIX        65     80
FT   STRAND       90     93
FT   TURN         99    101
FT   STRAND      106    110
FT   STRAND      113    115
FT   HELIX       116    122
FT   HELIX       127    146
FT   HELIX       156    158
FT   STRAND      159    161
FT   STRAND      167    169
FT   HELIX       189    191
FT   HELIX       195    198
FT   TURN        199    201
FT   HELIX       207    221
FT   HELIX       231    242
FT   HELIX       247    251
FT   HELIX       256    264
FT   HELIX       273    275
FT   HELIX       282    291
FT   TURN        296    298
FT   HELIX       302    307
FT   HELIX       309    311
FT   TURN        312    314
FT   HELIX       337    349
SQ   SEQUENCE   367 AA;  41940 MW;  EF680401D8E40610 CRC64;
     MSSPPPARSG FYRQEVTKTA WEVRAVYRDL QPVGSGAYGA VCSAVDGRTG AKVAIKKLYR
     PFQSELFAKR AYRELRLLKH MRHENVIGLL DVFTPDETLD DFTDFYLVMP FMGTDLGKLM
     KHEKLGEDRI QFLVYQMLKG LRYIHAAGII HRDLKPGNLA VNEDCELKIL DFGLARQADS
     EMTGYVVTRW YRAPEVILNW MRYTQTVDIW SVGCIMAEMI TGKTLFKGSD HLDQLKEIMK
     VTGTPPAEFV QRLQSDEAKN YMKGLPELEK KDFASILTNA SPLAVNLLEK MLVLDAEQRV
     TAGEALAHPY FESLHDTEDE PQVQKYDDSF DDVDRTLDEW KRVTYKEVLS FKPPRQLGAR
     VSKETPL
//
